# A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

> **NCT06671379** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 498 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** SHR-A2009 monotherapy
- **DRUG:** platinum-based dual-agent chemotherapy

## Key facts

- **NCT ID:** NCT06671379
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-29
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 498 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06671379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06671379, "A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06671379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*